Edgewise Therapeutics is a clinical-stage biopharmaceutical company (NASDAQ: EWTX) developing therapeutics for severe rare neuromuscular and cardiac disorders, with a focus on muscle biology and small molecule engineering.
Company Info
Upcoming Milestones & Key Dates
CIRRUS-HCM Phase 2 sevasemten HCM readout
Phase 3 FOX-DMD topline in DMD
Clinical Development Pipeline
Recent News
Edgewise Therapeutics' lead cardiac myosin modulator underwhelmed in a Phase 2 readout, sending shares lower and raising doubts about its competitive standing against BMS and Cytokinetics in the HCM space.
Edgewise Therapeutics announced plans to advance its lead cardiac drug into Phase 3 development following a positive mid-stage data update in patients with hypertrophic cardiomyopathy.
Leadership Team
President & CEO
Chief Financial Officer
Co-Founder & Chief Scientific Officer
Careers & Job Openings